October 16, 2026

Dear Payer, Clients, Health Plan Leadership, and Plan Negotiators:

We are writing to inform you of an upcoming change to the YUTREPIA (treprostinil) inhalation powder Prescribing Information. Due to recent developments in litigation, we are discontinuing promotion of YUTREPIA for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The litigation impacts the indication language with respect to PH-ILD only. Specifically, YUTREPIA will no longer be indicated for treatment of PH-ILD. Effective immediately, we ask you to deny any prior authorization request for the use of YUTREPIA for the treatment of PH-ILD.

Going forward, YUTREPIA will be indicated for treatment of pulmonary arterial hypertension (PAH) only. We will be introducing new referral and application forms for YUTREPIA and its patient support programs (including the voucher program) requiring healthcare practitioners to certify with a checkbox that the patient has Group 1 PAH. All prior forms are null and void, and should be replaced with the new forms.

We understand this update may cause confusion and are here to answer any questions you may have.

Sincerely,

Roger Jeffs

Chief Executive Officer

Liquidia Technologies, Inc. 419 Davis Drive, Morrisville, NC 27560

Phone - 919-328-4400